Positive Phase 3 Data on Stivarga in Gastrointestinal Stromal Tumors

Bayer HealthCare announced the results from a pivotal Phase 3 study for Stivarga (regorafenib); the GRID (GIST - Regorafenib In Progressive Disease) trial provides evidence for the efficacy of regorafenib in patients with gastrointestinal stromal tumor (GIST).

Sign In to MPR

SIGN IN WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

Sign in with your MPR account

Keep me signed in Forgot your password?

Don't have one of these accounts?

Create an account for free »

Register for free with MPR

REGISTER FOR FREE WITH ONE OF YOUR SOCIAL ACCOUNTS

OR

REGISTER FOR FREE WITH A MPR ACCOUNT

Registration acknowledges the Terms and Conditions and Privacy Policy

Already have an account?

Log in now »

FORGET YOUR PASSWORD?

Enter your MPR registration email address to receive a password reset link.

NEW PASSWORD SENT

Already have an account?

Log in now »

ALMOST DONE

Almost Done

Please confirm the information BELOW before Signing In

By registering you agree with our Terms and Conditions and Privacy Policy.

« CANCEL AND GO BACK

Thank you for registering with MPRxOnline.

Please take a moment to tell us a little more about yourself, so we can bring you specialized clinical content that’s most valuable to you.

NEED HELP? Contact Customer Service »